Opera Trading Capital trimmed its position in shares of Theralase Technologies Inc. (NASDAQ:TLT) by 50.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,955 shares of the company’s stock after selling 2,000 shares during the quarter. Opera Trading Capital’s holdings in Theralase Technologies were worth $244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Risk Paradigm Group LLC boosted its holdings in shares of Theralase Technologies by 1.1% in the 2nd quarter. Risk Paradigm Group LLC now owns 1,600 shares of the company’s stock worth $200,000 after buying an additional 17 shares during the last quarter. Almanack Investment Partners LLC. boosted its holdings in shares of Theralase Technologies by 1.9% in the 2nd quarter. Almanack Investment Partners LLC. now owns 1,321 shares of the company’s stock worth $165,000 after buying an additional 25 shares during the last quarter. Moller Financial Services boosted its holdings in shares of Theralase Technologies by 0.6% in the 2nd quarter. Moller Financial Services now owns 5,382 shares of the company’s stock worth $673,000 after buying an additional 33 shares during the last quarter. Oppenheimer & Co. Inc. boosted its holdings in shares of Theralase Technologies by 0.5% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 10,654 shares of the company’s stock worth $1,333,000 after buying an additional 54 shares during the last quarter. Finally, Pinnacle Financial Partners Inc. boosted its holdings in shares of Theralase Technologies by 4.2% in the 2nd quarter. Pinnacle Financial Partners Inc. now owns 1,755 shares of the company’s stock worth $220,000 after buying an additional 70 shares during the last quarter.

Shares of Theralase Technologies Inc. (NASDAQ TLT) traded down C$1.90 during trading hours on Monday, hitting C$124.10. 11,980,900 shares of the company were exchanged, compared to its average volume of 8,343,837. Theralase Technologies Inc. has a 52 week low of C$116.49 and a 52 week high of C$129.57.

The company also recently disclosed a monthly dividend, which was paid on Tuesday, November 7th. Investors of record on Thursday, November 2nd were paid a $0.2631 dividend. This is a boost from Theralase Technologies’s previous monthly dividend of $0.25. This represents a $3.16 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date was Wednesday, November 1st. Theralase Technologies’s payout ratio is currently 17.16%.

ILLEGAL ACTIVITY WARNING: “Opera Trading Capital Has $244,000 Holdings in Theralase Technologies Inc. (TLT)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/opera-trading-capital-has-244000-holdings-in-theralase-technologies-inc-tlt/1700244.html.

Theralase Technologies Profile

iShares 20+ Year Treasury Bond ETF (the Fund) is an exchange-traded fund. The Fund seeks to track the investment results of an index composed of United States Treasury bonds with remaining maturities greater than 20 years. The Fund seeks to track the investment results of the Barclays U.S. 20+ Year Treasury Bond Index (the Underlying Index), which measures the performance of public obligations of the United States Treasury that have a remaining maturity of 20 or more years.

Want to see what other hedge funds are holding TLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theralase Technologies Inc. (NASDAQ:TLT).

Institutional Ownership by Quarter for Theralase Technologies (NASDAQ:TLT)

Receive News & Ratings for Theralase Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.